Postherpetic Neuralgia

6
Pipeline Programs
6
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
6
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
2 programs
2
SPM 927Phase 21 trial
SPM927/LacosamidePhase 21 trial
Active Trials
NCT00238511CompletedEst. Jan 2005
NCT00861068Completed44Est. Jan 2003
Bial
BialPortugal - Coronado
1 program
1
Eslicarbazepine acetatePhase 21 trial
Active Trials
NCT00981227CompletedEst. Jan 2009
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
RetigabinePhase 21 trial
Active Trials
NCT00612105CompletedEst. Dec 2009
Pfizer
PfizerNEW YORK, NY
1 program
1
T-62Phase 21 trial
Active Trials
NCT00506610Withdrawn0
Xenon Pharmaceuticals
1 program
1
XPF-002Phase 21 trial
Active Trials
NCT01195636Completed70Est. Mar 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Xenon PharmaceuticalsXPF-002
BialEslicarbazepine acetate
Bausch HealthRetigabine
UCB PharmaSPM 927
UCB PharmaSPM927/Lacosamide

Clinical Trials (6)

Total enrollment: 114 patients across 6 trials

NCT00506610PfizerT-62

A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak

0
Phase 2Withdrawn
NCT01195636Xenon PharmaceuticalsXPF-002

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

Start: Aug 2010Est. completion: Mar 201170 patients
Phase 2Completed
NCT00981227BialEslicarbazepine acetate

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia

Start: Nov 2007Est. completion: Jan 2009
Phase 2Completed
NCT00612105Bausch HealthRetigabine

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

Start: Oct 2007Est. completion: Dec 2009
Phase 2Completed
NCT00238511UCB PharmaSPM 927

An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)

Start: Nov 2002Est. completion: Jan 2005
Phase 2Completed
NCT00861068UCB PharmaSPM927/Lacosamide

A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).

Start: Feb 2002Est. completion: Jan 200344 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space